Agilent Technologies, Inc. (NYSE:A) Position Lessened by Brown Shipley& Co Ltd

Brown Shipley& Co Ltd decreased its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 16.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,780 shares of the medical research company's stock after selling 4,735 shares during the period. Agilent Technologies accounts for 1.7% of Brown Shipley& Co Ltd's portfolio, making the stock its 20th largest position. Brown Shipley& Co Ltd's holdings in Agilent Technologies were worth $3,329,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. CKW Financial Group lifted its holdings in shares of Agilent Technologies by 114.9% in the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Global X Japan Co. Ltd. raised its stake in Agilent Technologies by 161.1% during the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after acquiring an additional 116 shares in the last quarter. Redwood Park Advisors LLC acquired a new position in Agilent Technologies during the 4th quarter worth $27,000. Lee Danner & Bass Inc. acquired a new position in Agilent Technologies during the 4th quarter worth $29,000. Finally, Hanson & Doremus Investment Management boosted its position in Agilent Technologies by 66.5% during the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock worth $35,000 after acquiring an additional 105 shares during the period.

Insider Transactions at Agilent Technologies

In other news, Director Daniel K. Podolsky sold 1,819 shares of Agilent Technologies stock in a transaction on Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the transaction, the director now owns 35,737 shares in the company, valued at approximately $4,161,931.02. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of Agilent Technologies stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. This represents a 8.05% decrease in their position. The disclosure for this sale can be found here.

Agilent Technologies Stock Down 4.1%

Shares of Agilent Technologies stock opened at $108.83 on Thursday. The stock's fifty day moving average is $109.98 and its 200-day moving average is $127.76. The firm has a market capitalization of $31.03 billion, a PE ratio of 25.02, a price-to-earnings-growth ratio of 3.20 and a beta of 1.27. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $154.49.

Agilent Technologies (NYSE:A - Get Free Report) last announced its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. The company had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Jefferies Financial Group reduced their price target on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research report on Monday, April 21st. Wells Fargo & Company dropped their price objective on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Barclays dropped their price objective on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. TD Cowen boosted their price objective on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. Finally, Robert W. Baird dropped their price objective on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $143.00.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.